Drugs for Cholangiocarcinoma (Bile Duct Cancer)

Here are the drugs and financial support services available to patients receiving treatment for Cholangiocarcinoma (Bile Duct Cancer).

Pemazyre (pemigatinib) Tablets

Drug company: Incyte

Pemazyre is a kinase inhibitor tablet used for the treatment of adults with previously treated, unresectable (cannot be removed by surgery) locally advanced or metastatic cholangiocarcinoma, a type of bile duct cancer, that is associated with an FGFR2 gene fusion or other rearrangements. Pemazyre is the first drug to be approved for cholangiocarcinoma with this type of genetic alterations.

Incyte offers 3 financial assistance programs for patients who have been prescribed Pemazyre:

Pemazyre Copay/Coinsurance Program

Eligible patients who have commercial or private insurance can receive Pemazyre for as little as $0 copay, with a maximum savings benefit of $9,000 per claim and $25,000 per year. Patients who have government insurance are not eligible for this program.

Pemazyre Patient Assistance Program

Eligible patients who have no insurance or have insurance that does not cover the cost of Pemazyre can receive Pemazyre for free if they meet the household and size and annual income criteria, including earning less than $125,000 per year, or less than 600% of the federal poverty level.

Pemazyre Temporary Access Program

Eligible patients who have commercial or private insurance and who experience a delay in coverage may receive a free 30-day supply of Pemazyre by submitting proof of their insurance claim verifying the delay.

Table. Drugs Prescribed for Cervical Cancer

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services

Share this:

Last modified: April 7, 2021

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.